SMA Market Snapshot: Future Spinraza Patent Loss Makes Room For Promising Myostatin Inhibitors

While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.